Liver Fibrosis in Primary Sjögren's Syndrome.

Autor:	Androutsakos T; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Voulgaris TA; Department of Gastroenterology, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens 'Laiko', Athens, Greece., Bakasis AD; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Koutsompina ML; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Chatzis L; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Argyropoulou OD; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Pezoulas V; Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.; Biomedical Research Section, Institute of Molecular Biology and Biotechnology, Ioannina, Greece., Fotiadis DI; Unit of Medical Technology and Intelligent Information Systems, University of Ioannina, Ioannina, Greece.; Biomedical Research Section, Institute of Molecular Biology and Biotechnology, Ioannina, Greece., Papatheodoridis G; Department of Gastroenterology, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens 'Laiko', Athens, Greece., Tzioufas AG; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Goules AV; Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Jun 15; Vol. 13, pp. 889021. Date of Electronic Publication: 2022 Jun 15 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.889021
Abstrakt:	Background: Primary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD), liver fibrosis (LF) may occur. No studies have explored the occurrence of LF in the context of NAFLD among pSS patients. Methods: Consecutive pSS patients from the rheumatology outpatient clinic of the Department of Pathophysiology and individuals evaluated in the hepatology outpatient clinic for possible NAFLD serving as comparators underwent transient elastography (TE) to assess LF and liver steatosis (LS). All participants had no overt chronic liver disease. Clinical, demographic, and laboratory data were collected from all participants at the time of TE. Results: Fifty-two pSS patients and 198 comparators were included in the study. The median age (range) of pSS and comparators was 62.5 (30-81) and 55 (19-86) years, respectively. Both groups had similar prevalence regarding type 2 diabetes mellitus, hyperlipidemia, and similar body mass index (BMI). Patients with pSS had less frequently high LS (S2, S3) (27% vs. 62%, p < 0.001) and significant LF (F2-4) [2 (3.8%) vs. 34 (17.2%), p = 0.014] than comparators. Univariable analysis showed that advanced LF was significantly associated with older age, higher LS, greater BMI, and disease status (comparators than pSS); of these, only age was identified as an independent LF risk factor in the multivariable logistic regression analysis. Conclusion: Liver fibrosis among pSS patients is most likely not attributed to the disease per se . Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Androutsakos, Voulgaris, Bakasis, Koutsompina, Chatzis, Argyropoulou, Pezoulas, Fotiadis, Papatheodoridis, Tzioufas and Goules.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu